Skin cancer in skin of color.
In general, skin cancer is uncommon in people of color when compared to Caucasians. When it does occur, it is often associated with increased morbidity and mortality. Differences in survival rates may be attributed to skin cancers being diagnosed at a more advanced stage, and socioeconomic factors such as lack of adequate insurance coverage and lack of transportation can function as barriers to timely diagnosis and early treatment. In addition to advanced stage at presentation, malignant skin lesions in skin of color often present in an atypical fashion. Because skin cancer prevention and screening practices historically have been lower among Hispanics, Blacks, and Asians, and given the changing demographics in the United States, interventions that are tailored to each of these groups will be needed. Public educational campaigns should be expanded to educate people of all skin types with emphasis on skin cancers occurring in areas not exposed to the sun (Byrd-Miles et al., 2007), since sunlight is not as important an etiologic factor in the pathogenesis of skin cancer in people of color. Dermatologists and primary care physicians should instruct their darker-skinned patients on how to perform routine skin self-examinations. Physicians should also encourage patients to ask their specialists such as their gynecologist, dentist, and ophthalmologist to look for abnormal pigmentation during routine exams. To reduce the burden of skin cancer, several prevention methods for all people have been strongly encouraged, including monthly self-examinations, daily use of SPF 30 or greater sunscreen, sunglasses with UV-absorbing lenses, and avoiding tanning booths (American Cancer Society, 2008) (see Table 7). In addition, recommendations for clinicians to promote the prevention of skin cancer in skin of color have also been made, including closely monitoring changing pigmented lesions on the palms and soles and hyperkeratotic or poorly healing ulcers in immunosuppressed patients (Halder & Bridgeman-Shah, 1995) (see Table 7).
Bradford
Porcia T
PT
Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
D006801:Humans; D001213:Asian; D001741:Black or African American; D002277:Carcinoma / Q000208:ethnology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D006630:Hispanic or Latino; D016410:Lymphoma, T-Cell, Cutaneous / Q000208:ethnology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D008545:Melanoma / Q000208:ethnology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D012307:Risk Factors; D012509:Sarcoma / Q000208:ethnology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D012878:Skin Neoplasms / Q000208:ethnology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D014481:United States / Q000453:epidemiology; D000095223:White
Clin Exp Dermatol. 2006 Jul;31(4):542-4
16716159
J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):33-9
10607317
J Am Acad Dermatol. 1991 Jun;24(6 Pt 1):929-37
1714469
J Am Acad Dermatol. 1991 Dec;25(6 Pt 1):1005-11
1810978
N Engl J Med. 2001 Mar 29;344(13):975-83
11274625
J Am Acad Dermatol. 2007 Sep;57(3):484-501
17512631
J Am Acad Dermatol. 2008 Aug;59(2):179-206; quiz 207-8
18638627
Photochem Photobiol. 2008 May-Jun;84(3):539-49
18435612
Cancer. 1995 Jan 15;75(2 Suppl):667-73
7804993
Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents
12794189
J Clin Oncol. 2008 Jan 1;26(1):66-75
18165642
Am J Med Genet. 1997 Mar 31;69(3):299-308
9096761
J Dermatol Surg Oncol. 1981 Jul;7(7):570-1
7251966
Cancer. 1984 Oct 1;54(7):1482-8
6467173
J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):355-74; quiz 375-6
8784271
Diabetes Care. 2008 Jul;31(7):e57
18594056
Curr Probl Cancer. 2008 Mar-Apr;32(2):43-87
18325433
J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4
17052479
J Drugs Dermatol. 2007 Jan;6(1):10-6
17373156
J Am Acad Dermatol. 2004 Jan;50(1):21-4; discussion 142-3
14699360
J Am Acad Dermatol. 1996 May;34(5 Pt 1):751-2
8632068
Cutis. 2001 May;67(5):403-6
11381857
Lancet Infect Dis. 2007 Apr;7(4):266-81
17376384
Aust N Z J Surg. 1971 Nov;41(2):140-7
5288412
Cancer. 2006 Mar 1;106(5):1162-8
16429450
Arch Dermatol. 2006 Jun;142(6):704-8
16785372
Arch Intern Med. 2006 Sep 25;166(17):1907-14
17000949
Cancer. 1981 Mar 15;47(6):1436-8
7226069
Arch Dermatol. 2007 Jul;143(7):854-9
17638728
Dermatol Clin. 2006 Oct;24(4):509-20, vii
17010779
Arch Dermatol. 1996 Mar;132(3):320-4
8607638
Int J Dermatol. 2007 Jul;46(7):754-6
17614810
JAMA. 1982 Oct 15;248(15):1856-9
7120604
Br J Dermatol. 2006 Apr;154(4):790-1
16536838
Cancer Causes Control. 2005 Dec;16(10):1253-9
16215876
J Cancer Educ. 1994 Summer;9(2):105-10
7917894
Dermatol Clin. 1988 Jul;6(3):397-405
3048822
Arch Dermatol. 1995 Feb;131(2):157-63
7857111
Mayo Clin Proc. 2007 Apr;82(4):490-513
17418079
Clin Exp Dermatol. 2003 Mar;28(2):138-41
12653697
Clin Exp Dermatol. 2003 Nov;28 Suppl 1:33-5
14616811
Oncogene. 2003 May 19;22(20):3042-52
12789279
J Med Virol. 2000 Jul;61(3):289-97
10861635
Cancer. 2008 Aug 1;113(3):616-27
18618615
Int J Dermatol. 1993 Sep;32(9):677-9
8407099
J Am Acad Dermatol. 1981 Nov;5(5):535-43
7298919
Arch Dermatol. 2009 Apr;145(4):427-34
19380664
N Engl J Med. 2005 Nov 24;353(21):2262-9
16306523